Alliance-A151216: Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

The purpose of the study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with the drugs that may specifically target tumors that have the genetic changes.

Learn more about Alliance-A151216 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Learn more about Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

NON-SMALL CELL

NRG-LU002: Maintenance systemic therapy versus consolidative stereotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non- small cell lung cancer (NSCLC); A Randomized Phase II/III Trial.

The purpose of this study is to compare any good and bad effects of using the usual drug therapy plus radiation to treat the lung cancer and the areas of metastasis (where the cancer has spread) compared with the usual drug therapy alone.

Learn more about the NRG-LU002 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

Alliance-A081105: Erlotinib hydrochloride in treating patients with stage IB- IIIA non-small cell lung cancer that has been completely removed by surgery (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

Learn more about Alliance-A081105 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

A081105: Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NonSmall Cell Lung Cancer (NSCLC)

Learn more about Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

ECOG/ACRIN E4512: Crizotinib in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and ALK fusion mutations (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effects of using the study drug, crizotinib (also known as Xalkori), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Learn more about ECOG/ACRIN E4512 trial or contact the Reading Hospital Protocol Office at 484-628-8193

E4512: A Phase III Double-Blind Trial of Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn more about Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

EA5163: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Learn more about Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Learn more about Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

Alliance-A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO.

The purpose of this study is to compare the usual treatment alone to using pembrolizumab plus the usual treatment.

Learn more about the Alliance-A081801 trial or call the Reading Hospital Protocol Office at 484-628-8193.

A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Learn more about Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

NCMGA0012-304/Incyte: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304).

The purpose of this study is to compare the effects and safety of INCMGA00012 in combination with chemotherapy (“investigational combination”) compared to placebo in combination with chemotherapy in participants with NSCLC.

Learn more about the INCMGA0012-304/Incyte trial or call the Reading Hospital Protocol Office at 484-628-8193.

S1714: Neuropathy Trial (Observational Study)

Eligibility: Stg I,II or III primary non-small cell lung cancer, breast cancer or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy.

The purpose of this study is to develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.

Learn more about the S1714 trail.

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)

Learn more about Lung-MAP: A Master Screening Protocol for PreviouslyTreated Non-Small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office.

S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Learn more about Rucaparib in Treating Patients With Genomic LOH High and/or
Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

S1900B: A Phase II Study of Loxo-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Sub-Study)

Learn more about Targeted Treatment for RET Fusion-Positive Advanced Non-Small
Cell Lung Cancer (A LUNG-MAP Treatment Trial)
 or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

SMALL CELL

NRG-CC003: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation.

Learn more about the NRG-CC003 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

NRG-LU005: Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

The purpose of this study is to compare the usual treatment to atezolizumab plus the usual treatment.

Learn more about the NRG-LU005 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

NON- SQUAMOUS

S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)

Learn more about the Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.